FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Moderna Announces its Coronavirus Vaccine is 94.5% Effective”
Moderna (NASDAQ: MRNA) stock shot up over 12% in premarket trading as its COVID-19 Vaccine Candidate Met its Primary Efficacy Endpoint in the First Interim Analysis of its Phase 3 Study.
Known as the COVE study, it enrolled more than 30,000 participants in the U.S. and results show that the vaccine candidate met the statistical criteria with an efficacy of 94.5%, and Moderna now intends to apply for an Emergency Use Authorization with U.S. FDA in the coming weeks.
Moderna is working with the U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson, a COVID-19 vaccine distributor contracted by the U.S. government, as well as global stakeholders to be prepared for distribution of mRNA-1273, in the event that it receives an Emergency Use Authorization and/or similar global authorizations. The Company is also working closely with the U.S. Food and Drug Administration (FDA) to submit data from its ongoing stability testing for approval.
For more information, please visit: Moderna, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.